Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy
- Correspondence to Dr Rishi P Singh, Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, i-32, Cleveland OH 44195, USA; singhr{at}ccf.org
-
Contributors All authors contributed to the writing and editing of this manuscript.
- Accepted 27 June 2011
- Published Online First 3 November 2011
Abstract
Chronic central serous retinopathy (CSR) is characterised by frequent exacerbations and a poor visual prognosis. Very few therapies exist for chronic CSR, and the existing therapies are often ineffective. Thus, novel therapies to combat this frustrating disorder are needed. Presented here is a case detailing a patient with chronic CSR with persistent subfoveal fluid of 2 years' duration that completely resolved with 1 month of oral rifampin therapy. As a cytochrome P450, 3A4 inducer, rifampin is thought to favourably alter the metabolism of endogenous steroids, thereby leading to an improvement in CSR manifestations.
- Rifampin
- central serous retinopathy
- CYP450
- 3A4 inducer
- endogenous steroid metabolism
- retina
- vitreous
Footnotes
-
Competing interests None.
-
Patient consent Obtained.
-
Provenance and peer review Not commissioned; externally peer reviewed.
